RCUS
Arcus Biosciences Inc
24.70$
+1.2%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 74.0% | 75.9% | 82.3% | 86.2% | 90.0% | 88.3% | 89.2% | 88.0% | 88.0% | 88.4% | 84.7% | 81.8% | |
| 15.4% | 11.6% | 14.3% | 13.2% | 16.1% | 13.0% | 16.6% | 23.1% | 24.4% | 19.5% | 20.2% | 16.2% | |
| 67.1% | 69.3% | 77.0% | 81.7% | 87.0% | 85.0% | 86.2% | 84.7% | 85.3% | 86.1% | 82.4% | 76.0% | |
| 4.7% | 3.8% | 3.1% | 2.8% | 1.7% | 2.2% | 1.8% | 1.9% | 1.4% | 1.4% | 0.7% | 3.9% | |
| -17.4% | – | – | – | – | – | – | – | – | – | – | – | |
| 4.2% | – | – | – | – | – | – | – | – | – | – | – | |
| 56.3% | 57.8% | 45.3% | 46.5% | 54.9% | 57.8% | 54.1% | 48.9% | 55.2% | 44.6% | 47.4% | 49.8% | |
| 16.8% | 16.8% | 15.8% | 16.8% | 17.2% | 19.7% | 16.6% | 19.5% | 24.1% | 20.3% | 21.0% | 21.4% | |
| 0.8% | 1.0% | 0.9% | 0.9% | 0.9% | 1.0% | 1.0% | 1.1% | 1.3% | 1.1% | 1.3% | 1.4% | |
| 1.4% | 1.6% | 1.2% | 1.3% | 1.0% | 1.6% | 1.9% | 2.7% | 4.3% | 3.7% | 3.9% | 3.7% | |
| – | – | – | – | 3.8% | 4.2% | 4.2% | 9.0% | 10.1% | 8.7% | 10.0% | 10.9% | |
| 43.7% | 42.2% | 54.7% | 53.5% | 45.1% | 42.2% | 45.9% | 51.1% | 44.8% | 55.4% | 52.6% | 50.2% | |
| -64.5% | -77.5% | -66.0% | -79.8% | -82.9% | -98.4% | -107.6% | -115.7% | -141.6% | -130.4% | -161.8% | -184.4% | |
| 6.3% | 6.8% | 6.7% | 7.7% | 7.3% | 8.0% | 8.5% | 9.9% | 10.9% | 9.4% | 12.6% | 13.6% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.